急性胰臟炎市場 - 全球及區域 - 分析與預測（2025-2035）

急性胰臟炎是胰臟突然發炎，通常由膽結石或過量攝取酒精引起。

這種疾病會引起劇烈的腹痛、噁心和嘔吐，在某些情況下還會導致器官衰竭和休克等全身性併發症。如果不及時治療，可能會發展為嚴重的急性胰臟炎，並因多重器官衰竭和感染疾病等併發症而導致死亡的高風險。隨著藥物治療、早期診斷和支持性治療的進步改善患者的預後，全球急性胰臟炎市場不斷擴大。傳統上，急性胰臟炎採用輸液、疼痛管理和營養支持等支持性治療進行治療。然而，針對發炎、酵素抑制和器官保護的新型藥物療法改變治療模式。

急性胰臟炎藥物治療市場受到多種因素的推動，包括由於膽結石、酒精消費和肥胖等增加而導致的全球胰臟炎發病率上升，以及人們越來越意識到需要更有效的治療方法來預防胰臟壞死、感染疾病和器官衰竭等併發症。

急性胰臟炎市場的主要促進因素之一是肥胖、膽結石和酗酒等風險因素的日益普遍，這些因素導致胰臟炎發病率上升。隨著越來越多的患者尋求急性胰臟炎治療，對能夠減輕病情、改善康復並預防重症胰臟炎進展的藥物干預的需求也日益成長。針對發炎反應中關鍵細胞激素和路徑的抗發炎藥物已成為減輕急性胰臟炎嚴重程度和預防胰臟壞死和感染疾病等併發症的關鍵。

除了急性治療外，目的是保護胰臟和減少器官衰竭的藥物也備受關注。胰臟酶抑制劑和細胞激素抑制劑已成為重要的治療選擇，有助於減少胰臟內酶活化的有害影響並預防全身性發炎。這些治療藥物有望在急性胰臟炎的治療和最大程度減少長期併發症發揮重要作用，進一步擴大市場。

此外，早期診斷工具和免疫調節療法的進步也促進了市場擴張。用於早期發現重症胰臟炎的生物標記和影像技術的開發，將使介入措施更具針對性、更及時，改善患者預後。針對胰臟炎早期階段的藥物，著重於免疫調節和組織修復，將為減緩疾病進展提供新的選擇，預計將進一步加速市場擴張。

儘管急性胰臟炎市場成長前景光明，但挑戰依然存在，例如創新治療方法的高昂成本，這可能會限制資源匱乏地區患者獲得治療。此外，急性胰臟炎治療的複雜性需要專科護理，患者對酵素抑制劑和抗發炎藥物等治療的反應差異很大，這仍然是個挑戰。然而，進行的抗發炎、免疫調節和酵素標靶治療藥物研發為改善急性胰臟炎治療和推動市場成長提供了重要機會。

急性胰臟炎市場穩步成長，主要企業採用各種策略來獲得競爭優勢，致力於創新治療方法、早期診斷和先進的藥物輸送系統。

急性胰臟炎市場快速發展，幾個關鍵趨勢推動其成長。其中之一是抗發炎療法的開發，因為各公司努力解決急性胰臟炎背後的發炎問題。另一個關鍵趨勢是開發先進的藥物傳輸系統，以提高治療的有效性和安全性。最後，復健和恢復性治療也日益受到關注。這些趨勢預示著急性胰臟炎市場正轉向更具針對性、個人化和綜合性的治療方法，目的是改善急性管理和長期復原。

本報告研究了全球急性胰臟炎市場，並提供了市場概述、區域趨勢和參與市場的公司概況。

目錄

執行摘要

第1章 全球急性胰臟炎市場：產業展望

• 市場概覽
• 急性胰臟炎流行病學分析
• 監管狀況
• 主要趨勢
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場限制
  • 市場機會

第2章 全球急性胰臟炎市場（依地區，百萬美元，2023-2035）

• 北美洲
• 歐洲
• 亞太地區

第3章 競爭格局與公司概況

• 競爭格局
  • 關鍵策略和發展
• 公司簡介
  • CalciMedica, Inc.
  • Arrivo BioVentures LLC
  • Lamassu Pharma, LLC.
  • Dr. Falk Pharma GmbH

第4章 調查方法

Global Acute Pancreatitis Market, Analysis and Forecast: 2025-2035

Acute pancreatitis is a sudden inflammation of the pancreas, often caused by gallstones or excessive alcohol consumption. The condition can lead to severe abdominal pain, nausea, vomiting, and in some cases, systemic complications such as organ failure and shock. If not treated promptly, it can progress to severe acute pancreatitis, which carries a high risk of mortality due to complications such as multi-organ failure and infection. The global market for acute pancreatitis is growing as advancements in pharmaceutical therapies, early diagnosis, and supportive care are improving patient outcomes. Traditionally, the management of acute pancreatitis involved supportive care such as intravenous fluids, pain management, and nutritional support. However, new drug therapies targeting inflammation, enzyme inhibition, and organ protection are transforming the treatment landscape.

The market for pharmaceutical treatments in acute pancreatitis is driven by several factors, including the increasing incidence of pancreatitis globally, especially due to rising rates of gallstones, alcohol consumption, and obesity. There is also a growing recognition of the need for more effective therapies aimed at preventing complications, such as pancreatic necrosis, infection, and organ failure.

One of the main drivers for the acute pancreatitis market is the increasing prevalence of risk factors such as obesity, gallstones, and alcohol abuse, which are contributing to a higher incidence of the condition. As more patients seek treatment for acute pancreatitis, there is a rising demand for pharmaceutical interventions that can reduce the severity of the disease, improve recovery, and prevent the progression to severe pancreatitis. Anti-inflammatory drugs that target key cytokines and pathways involved in the inflammatory response are becoming essential in reducing the severity of acute pancreatitis and preventing complications like pancreatic necrosis and infections.

In addition to acute care treatments, drugs aimed at protecting the pancreas and mitigating organ failure are gaining attention. Pancreatic enzyme inhibitors and cytokine inhibitors are emerging as important therapeutic options, helping to reduce the harmful effects of enzyme activation within the pancreas and preventing systemic inflammation. These therapies are expected to play a crucial role in managing acute pancreatitis and minimizing long-term complications, further expanding the market.

Moreover, advancements in early diagnostic tools and immunomodulatory therapies are contributing to market growth. The development of biomarkers and imaging technologies for the early detection of severe pancreatitis allows for more targeted and timely interventions, improving patient outcomes. Pharmaceuticals that target the early stages of the disease, focusing on immunomodulation and tissue repair, are expected to further accelerate market expansion, providing new options to reduce disease progression.

Despite the promising growth of the acute pancreatitis market, challenges remain, including the high cost of innovative treatments, which may limit access for patients in resource-limited settings. The complexity of treating acute pancreatitis also requires specialized care, and variability in patient responses to treatments such as enzyme inhibitors or anti-inflammatory agents continues to be a challenge. However, ongoing research and development in anti-inflammatory, immunomodulatory, and enzyme-targeted therapies provide significant opportunities for market growth and improving the management of acute pancreatitis.

The acute pancreatitis market is experiencing steady growth, with key players adopting various strategies to gain a competitive edge, focusing on innovative therapies, early diagnosis, and advanced drug delivery systems.

The acute pancreatitis market is evolving rapidly, with several key trends driving its growth. One of the main focuses is on the development of anti-inflammatory therapies, as companies seek to address the inflammation that underpins acute pancreatitis. Another key trend is the development of advanced drug delivery systems that improve the efficacy and safety of treatments. Lastly, there is an increasing focus on rehabilitation and recovery therapies. Together, these trends indicate a shift toward more targeted, personalized, and comprehensive treatment approaches, aiming to improve both acute management and long-term recovery outcomes in the acute pancreatitis market.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Key Questions Answered

Analysis and Forecast Note

1. Global Acute Pancreatitis Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Epidemiological Analysis of Acute Pancreatitis
• 1.3 Regulatory Landscape
• 1.4 Key Trends
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraint
  • 1.6.4 Market Opportunities

2. Global Acute Pancreatitis Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 North America Acute Pancreatitis Market, by Country
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
    • 2.2.2.1 Europe Acute Pancreatitis Market, by Country
      • 2.2.2.1.1 Germany
      • 2.2.2.1.2 U.K.
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
    • 2.3.2.1 Asia-Pacific Acute Pancreatitis Market, by Country
      • 2.3.2.1.1 Japan

3. Competitive Landscape and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations and Business Expansions
• 3.2 Company Profiles
  • 3.2.1 CalciMedica, Inc.
    • 3.2.1.1 Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers
    • 3.2.1.4 Key Personnel
    • 3.2.1.5 Analyst View
  • 3.2.2 Arrivo BioVentures LLC
    • 3.2.2.1 Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers
    • 3.2.2.4 Key Personnel
    • 3.2.2.5 Analyst View
  • 3.2.3 Lamassu Pharma, LLC.
    • 3.2.3.1 Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers
    • 3.2.3.4 Key Personnel
    • 3.2.3.5 Analyst View
  • 3.2.4 Dr. Falk Pharma GmbH
    • 3.2.4.1 Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers
    • 3.2.4.4 Key Personnel
    • 3.2.4.5 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Acute Pancreatitis Market, Market Overview
• Figure: Global Acute Pancreatitis Market, Epidemiological Analysis
• Figure: Global Acute Pancreatitis Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Acute Pancreatitis Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table: Global Acute Pancreatitis Market, Regulatory Scenario
• Table: Global Acute Pancreatitis Market Dynamics, Impact Analysis